Harpoon Medical to Present an Update on Early Feasibility Study with 1-year Follow-up at the 2016 EACTS Congress

BALTIMORE, Sept. 27, 2016 /PRNewswire/ -- Harpoon Medical, Inc., developer of the Harpoon Medical Mitral Valve Repair System for minimally-invasive, beating heart mitral valve repair using artificial ePTFE cords, has been invited to present an update on the patients enrolled in the company's Early Feasibility Study at the upcoming European Association for Cardio-Thoracic Surgery (EACTS) Congress in Barcelona.

Logo - http://photos.prnewswire.com/prnh/20160926/412158LOGO [http://photos.prnewswire.com/prnh/20160926/412158LOGO]

Interim results from the first eleven patients enrolled in Harpoon Medical's Early Feasibility Study as of December 31, 2015 were published by Gammie et al. in Circulation (http://dx.doi.org/10.1161/CIRCULATIONAHA.116.022010 [http://circ.ahajournals.org/content/134/3/189]). Dr. Krzysztof Bartus, Associate Professor of Medicine Jagellonian University John Paul II Hospital, will provide an update on the results of the study at the EACTS Techno College during a session from 15:30-18:00 on Saturday, October 1, 2016. The presentation will include 6-month follow-up data on all thirteen patients enrolled in the study and 1-year follow-up data collected through August 31, 2016.

"I am excited to share Jagellonian University's early experience with the Harpoon device," said Dr. Bartus. "Together with our colleagues from the Institute of Cardiology in Warsaw we have enrolled thirteen patients in the Early Feasibility Study with excellent results and I think the intermediate term data that will be presented at EACTS is quite compelling."

"We are very happy with the performance of the Harpoon Mitral Valve Repair System to date," said Dr. James Gammie, Chief of Cardiac Surgery at the University of Maryland and the founder of Harpoon Medical. "The intermediate term follow-up results through six and twelve months are very exciting and we are confident that the device will provide a less invasive alternative to conventional mitral valve surgery for patients with degenerative mitral regurgitation."

About Harpoon Medical, Inc.Harpoon Medical, Inc. is a privately held medical device company commercializing a minimally invasive, image-guided technology for beating-heart mitral valve repair using artificial ePTFE cords. The technology was developed in the division of Cardiac Surgery at The University of Maryland School of Medicine. With the Harpoon Mitral Valve Repair System, surgeons are able to access and repair the mitral valve in a beating heart through a small incision between the ribs without the need for cardiac arrest or cardiopulmonary bypass. The Harpoon Mitral Valve Repair System is not approved for sale in any jurisdiction and is only available for use as part of an approved clinical study.

Photo: https://photos.prnewswire.com/prnh/20160926/412158LOGO

Harpoon Medical, Inc.

CONTACT: Peter Boyd, 410-346-5687 x103, pboyd@harpoonmedical.com

PR Newswire

Dit persbericht is via ANP Pers Support naar internationale (vak en online) media gestuurd. Heb je nieuws voor buitenlandse journalisten? Bekijk dan onze mogelijkheden of neem contact met ons op.

Verstuur nu éénmalig een persbericht

Verstuur persberichten en beeldmateriaal naar redacties in binnen- en buitenland. Via het ANP-net, het internationale medianetwerk van PR Newswire of met een perslijst op maat.

Direct persbericht versturen
070 - 41 41 234